Clinical and Translational Oncology

, Volume 14, Issue 10, pp 721–725 | Cite as

Surveillance of resected non-small cell lung cancer

  • A. López-González
  • P. Ibeas Millán
  • B. Cantos
  • M. Provencio
Educational Series – Red Series* New Trends in Clinical Oncology


Lung cancer is the most common cancer in the world. 15 % of all patients with lung cancer are diagnosed at an early stage, and surgery is the treatment of choice for them. 40 % of all patients survive more than 5 years after surgery, and most of them die as a result of systemic disease. Half of all recurrences are diagnosed within the first 24 months after curative treatment, and 90 % in the first 5 years. Despite this, it is not standardized who should do the monitoring, what additional tests are needed and how often should they be performed. We present here a review on the various recommendations in clinical guidelines.


Surveillance Non-small cell lung cancer 


  1. 1.
    Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909CrossRefGoogle Scholar
  2. 2.
    Mountain CF (1986) A new international staging system for lung cancer. Chest 89:225–233Google Scholar
  3. 3.
    Harpole DH (1995) A prognostic model of recurrence and death in stage I non-small cell lung utilizing presentation histopathology and oncoprotein expression. Cancer Res 55:51–56PubMedGoogle Scholar
  4. 4.
    Pairolero PC (1984) Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 38:331–336PubMedCrossRefGoogle Scholar
  5. 5.
    Virgo KS (1996) Cost of patient follow-up after potentially curative lung cancer treatment. J Thorac Cardiovasc Surg 112:356–363PubMedCrossRefGoogle Scholar
  6. 6.
    Shields TW (1978) Long-term survivors after resection of lung carcinoma. J Thorac Cardiovasc Surg 76:439–445PubMedGoogle Scholar
  7. 7.
    Frank A et al (1995) Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 32(5):1495–1512PubMedCrossRefGoogle Scholar
  8. 8.
    Di Maio M (2010) Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer 46(4):735–743PubMedCrossRefGoogle Scholar
  9. 9.
    Jemal A, Thomas A, Murray T (2002) Cancer statistics 2002. CA Cancer J Clin 52:23–45PubMedCrossRefGoogle Scholar
  10. 10.
    Lamont JP (2002) Systematic postoperative radiologic follow-up in patients with non-small cell lung cancer for detecting second primary lung cancer in stage IA. Arch Surg 137(8):935–938PubMedCrossRefGoogle Scholar
  11. 11.
    Gilbert S et al (2000) Who should follow up lung cancer patients after operation? Ann Thorac Surg 69:1696–1700PubMedCrossRefGoogle Scholar
  12. 12.
    Varela G (1998) Follow-up of patients with non-small-cell pulmonary cancer undergoing complete resection. Should surgeons be in charge? Arc Bronconeumol 34(1):14–6Google Scholar
  13. 13.
    Moore S et al (2002) Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ 325:1145–1152PubMedCrossRefGoogle Scholar
  14. 14.
    Naunheim KS (1995) Clinical surveillance testing after lung cancer operations. Ann Thorac Surg 60:1612PubMedCrossRefGoogle Scholar
  15. 15.
    Virgo KL (1995) Post-treatment management options for patients with lung cancer. Ann Surg 222:700–710PubMedCrossRefGoogle Scholar
  16. 16.
    Walsh GL (1995) Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg 60(6):1563–1570PubMedCrossRefGoogle Scholar
  17. 17.
    Younes R (1999) Follow-up in lung cancer: how often and for what purpose? Chest 115(6):1494–1499PubMedCrossRefGoogle Scholar
  18. 18.
    Egermann U (2002) Regular follow-up after curative resection of non-small cell lung cancer: a real benefit for patients. Eur Respir J 19(3):464–468PubMedCrossRefGoogle Scholar
  19. 19.
    Westeel V et al (2007) Protocole IFCT-0302: essai randomise de deux schémas de surveillance dans les cancers bronchiques non à petites cellules complètement réséqués. Rev Mal Respir 24:645–652PubMedCrossRefGoogle Scholar
  20. 20.
    Tufman A et al (2010) Biological markers in lung cancer: a clinician’s perspective. Cancer Biomark 6(3–4):123–135PubMedGoogle Scholar
  21. 21.
    Ghosal R et al (2009) A review of novel biological tools used in screening for the early detection of lung cancer. Postgrad Med J 85(1005):358–363PubMedCrossRefGoogle Scholar
  22. 22.
    Cho S, Lee EG (2010) A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small-cell lung cancer in asymptomatic patients. J Thorac Cardiovasc Surg 139(6):1447–1451PubMedCrossRefGoogle Scholar
  23. 23.
    Isobe K et al (2009) Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients. Int J Clin Oncol 14(6):497–501PubMedCrossRefGoogle Scholar
  24. 24.
    Kanzaki R et al (2010) Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact Cardiovasc Thorac Surg 10(6):1009–1014PubMedCrossRefGoogle Scholar
  25. 25.
    Rosell R (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967PubMedCrossRefGoogle Scholar
  26. 26.
    Carlson JJ (2009) Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 135(11):1483–1493PubMedCrossRefGoogle Scholar
  27. 27.
    Dahabreh IJ (2010) Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 16(1):291–303PubMedCrossRefGoogle Scholar
  28. 28.
    Massarelli E (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13(10):2890–2896PubMedCrossRefGoogle Scholar
  29. 29.
    Linardou H (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9(10):962–972PubMedCrossRefGoogle Scholar
  30. 30.
    Takeda M (2010) De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer. J Thorac Oncol 5(3):399–400PubMedCrossRefGoogle Scholar
  31. 31.
    Carpagnano GE et al (2008) New biomolecular methodologies in diagnosis of lung cancer. Recenti Prog Med 99(9):417–421PubMedGoogle Scholar
  32. 32.
    Han W et al (2009) Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients. Respir Res 25(10):86CrossRefGoogle Scholar
  33. 33.
    Belinsky SA et al (2002) Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62(8):2370–2377PubMedGoogle Scholar
  34. 34.
    Horváth I et al (2009) Exhaled biomarkers in lung cancer. Eur Respir J 34(1):261–275PubMedCrossRefGoogle Scholar
  35. 35.
    Carpagnano GE et al (2010) Cigarette smoke and increased COX-2 and surviving levels in exhaled breath condensate of lung cancer patients: how hot is the link? Lung Cancer 67(1):108–113PubMedCrossRefGoogle Scholar
  36. 36.
    Hsu HS et al (2007) Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J Pathol 213(4):412–419PubMedCrossRefGoogle Scholar
  37. 37.
    Gomperts BN et al (2010) Lung cancer biomarkers: FISHing in the sputum for risk assessment and early detection. Cancer Prev Res (Phila Pa) 3(4):420–423CrossRefGoogle Scholar
  38. 38.
    Varella-Garcia M et al (2010) The detection of chromosomal aneusomy by fluorescence in situ hybridation in sputum predicts lung cancer incidence. Cancer Prev Res (Phila Pa) 3(4):447–453CrossRefGoogle Scholar
  39. 39.
    Wang H et al (2010) Expression of Hsp27 and Hsp70 in lymphocytes and plasma in healthy workers and coal miners with lung cancer. J Huazhong Univ Sci Technolog Med Sci 30(4):415–420PubMedCrossRefGoogle Scholar
  40. 40.
    Gube M et al (2011) Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 85(3):185–192Google Scholar
  41. 41.
    Hsu HS et al (2007) Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 110(9):2019–2026PubMedCrossRefGoogle Scholar
  42. 42.
    Gao K (2009) Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One 4(6):e5875PubMedCrossRefGoogle Scholar
  43. 43.
    Rubins J et al (2007) Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 132(3 Suppl):355S–367SPubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012

Authors and Affiliations

  • A. López-González
    • 1
  • P. Ibeas Millán
    • 1
  • B. Cantos
    • 1
  • M. Provencio
    • 1
  1. 1.Servicio Oncología MédicaHospital Universitario Puerta de Hierro MajadahondaMadridSpain

Personalised recommendations